CALPORTA THERAPEUTICS
Calporta is developing selective small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases. Mutations that cause NPC lead to impaired intracellular lipid trafficking and lead to lysosomal accumulation of cholesterol and biolipds. TRPML1 is an ion channel in the lysosome and a key regulator of lysosomal trafficking processes. Impaired TRPML1 function has been... implicated in multiple pathological conditions, including NPC. Agonists of TRPML1 restore calcium efflux and normalize lysosomal trafficking and function. In addition to NPC and other lysosomal storage diseases, agonists of TRPML1 may have broad potential in other diseases such as muscular dystrophy and various taopathies such as Alzheimer's disease. Calporta's approach is based on research from the lab of Haoxing Xu, Ph.D., at the University of Michigan.
CALPORTA THERAPEUTICS
Industry:
Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
La Jolla, California, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
10 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 Google Google Cloud DigiCert SSL Pound Sterling Microsoft Japanese Yen
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Employees Featured
Investors List
Avalon Ventures
Avalon Ventures investment in Series A - Calporta Therapeutics
GSK
GSK investment in Series A - Calporta Therapeutics
More informations about "Calporta Therapeutics"
Calporta Therapeutics - Crunchbase Company Profile & Funding
Organization. Calporta Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Calporta is developing selective …See details»
Merck acquires Calporta Therapeutics for its autophagy-boosting …
Nov 17, 2019 Merck & Co. will spend up to $576 million to acquire Calporta Therapeutics, a San Diego–based start-up that is developing small molecules to boost autophagy, the process of …See details»
Merck acquires Calporta Therapeutics for $576m
Nov 14, 2019 Calporta Therapeutics is a portfolio company of COI Pharmaceuticals, a venture-pharma entity established by venture capital firm Avalon Ventures. The company develops small molecule agonists of transient …See details»
Calporta Therapeutics, Inc. Company Profile | La Jolla, CA ...
Find company research, competitor information, contact details & financial data for Calporta Therapeutics, Inc. of La Jolla, CA. Get the latest business insights from Dun & Bradstreet.See details»
Merck buys Calporta for preclinical neurodegeneration …
Nov 13, 2019 Merck has struck a deal to buy Calporta Therapeutics for up to $576 million. The takeover centers on TRPML1 agonists designed to treat …See details»
Calporta Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Jul 9, 2023 Explore Calporta Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 7 news, Disease Domain:Endocrinology and Metabolic Disease, Nervous …See details»
Merck builds in CNS diseases with $576m Calporta buy
3 days ago The bolt-on deal gives Merck access to a series of preclinical-stage TRPML1 agonists which Calporta is developing as treatments for various lysosomal storage and …See details»
COI Pharmaceuticals Announces Acquisition of Calporta by Merck
Nov 13, 2019 SAN DIEGO--(BUSINESS WIRE)-- COI Pharmaceuticals, the Community Of Innovation established by Avalon Ventures, today announced the acquisition of Calporta …See details»
Merck to acquire Calporta Therapeutics for $576m
In June this year, Merck signed an agreement to acquire biopharmaceutical firm Tilos Therapeutics in a deal valued at around $773m (£608m). Tilos Therapeutics is involved in the development of therapeutics, which targets the latent TGFβ …See details»
Merck Acquires Neurodegenerative Biotech Calporta
Nov 14, 2019 Merck has acquired Calporta Therapeutics, Inc., a San Diego biotech focused on developing drugs that support lysosome function, which could combat diseases (including …See details»
Calporta Therapeutics 2025 Company Profile: …
Calporta Therapeutics General Information Description. Developer of medicinal product designed to offer treatment of niemann-pck C disease. The company's products include selective small molecule agonists of transient receptor …See details»
Merck buys San Diego’s Calporta for up to $576 million
Nov 13, 2019 Calporta Therapeutics, one of eight San Diego biotech companies Avalon Ventures created with GlaxoSmithKline, has been sold to Merck for up to $576 million. The …See details»
Merck Acquires TRPML1 Agonist Developer Calporta for Up to …
Nov 13, 2019 Merck & Co. has acquired Calporta, a developer of treatments for neurodegenerative and lysosomal storage disorders, for up to $576 million from an entity …See details»
Merck Snaps Up Preclinical Neurodegenerative Asset in $576
Nov 13, 2019 Atmosphere1 / Shutterstock . Merck plunked down $576 million to acquire San Diego-based Calporta to gain access to preclinical TRPML1 agonists that are seen as …See details»
Merck acquires autophagy start-up | C&EN Global Enterprise
Merck & Co. will spend up to $576 million to acquire Calporta Therapeutics, a San Diego–based start-up that is developing small molecules to boost autophagy, the process of cellular self …See details»
Calporta Therapeutics - 2025 Company Profile - Tracxn
May 5, 2025 Calporta Therapeutics is developing small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for the treatment of rare …See details»
Merck Snaps Up Preclinical Neurodegenerative Asset in $576
Nov 13, 2019 Calporta Therapeutics focuses on the development of selective small-molecule agonists to TRPML1 (transient receptor potential cation channel, mucolipin subfamily), which …See details»
Merck snaps up COI's Calporta for $576M | 2019-11-14 - BioWorld
Nov 14, 2019 Merck & Co. Inc. acquired Calporta Therapeutics Inc. for an up-front payment and milestone payments that could total $576 million. Calporta is a build-to-buy spinout of La Jolla, …See details»
Research programme: lysosomal storage disorder therapeutics
Developer Calporta Therapeutics; University of Michigan Class Small molecules Mechanism of Action MCOLN1 protein modulators Orphan Drug Status Orphan designation is assigned by a …See details»
AbbVie Sells $30B of Bonds; Merck acquire's Calporta; GSK's IL-5 …
Nov 14, 2019 Merck has struck a deal to buy Calporta Therapeutics for up to $576 million. The takeover centres on TRPML1 agonists designed to treat neurodegenerative disorders by …See details»